The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: A PET study

Psychopharmacology

Volumn 131, Issue 2, 1997, Pages 148-152

  Kapur, Shitij ^a   Zipursky, Robert ^a   Roy, Paul ^a   Jones, Corey ^a   Remington, Gary ^a   Reed, Ken ^b   Houle, Sylvain ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

11C Raclopride; Dopamine D2 receptor; Haloperidol; Plasma levels; Positron Emission Tomography (PET); Receptor occupancy

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; RACLOPRIDE;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DYSTONIA; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HYPERSALIVATION; MALE; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; PLASMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOIDISM; SCHIZOPHRENIA; BINDING COMPETITION; BLOOD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT;

ADMINISTRATION, ORAL; ADULT; BINDING, COMPETITIVE; FEMALE; HALOPERIDOL; HUMANS; MALE; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030613524     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050277     Document Type: Article

References (22)

1. Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980) Extrapyramidal symptom rating scale (ESRS). Can J Neurol Sci 7:233-243
2. 2 dopamine receptor binding in the living brain by PET. Science 231:258-261
3. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
4. Freudenreich O, McEvoy JP (1995) How much haldol D does Larry really need? J Clin Psychiatry 56:331-332
5. 11C]-raclopride binding using a bolus plus infusion protocol. In: Myers R, Cunningham B, Bailey D, Jones T (eds) Quantification of brain function using PET. Academic Press, San Diego, pp 262-265
6. Janicak P, Javaid J, Davis J (1993) Neuroleptic plasma levels: methodological issues, study design, and clinical applicability. In: Marder S, Davis J, Janicak P (eds) Clinical use of neuroleptic plasma levels. American Psychiatric Press, Washington, D.C.
7. Janicak PG, Javaid JI, Sharma RP, Leach A, Dowd S, Davis JM (1995) A double-blind randomized study of three haloperidol plasma levels for acute psychosis. New Research Program and Abstracts 148 Annual Meeting of the American Psychiatric Association. Washington, D.C.
8. 2-dopamine receptors. Biol Psychiatry 39:515
9. 2 receptor occupancy with low dose haloperidol treatment: a PET study. Am J Psychiatry 153:948-950
10. 2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology (in press)
11. McEvoy JP, Hogarty GE, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48:739-745
12. 11C-raclopride binding in healthy young adults and schizophrenic patients reliability and age effects. Hum Psychopharmacol 7:157-165
13. 2-dopamine receptor occupancy in relation to antipsychotic drug effects a double-blind PET study of schizophrenic patients. Biol Psychiatry 33: 227-235
14. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 152:173-178
15. 4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol 291:59-66
16. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717-719
17. Stone CK, Garver DL, Griffith J, Hirschowitz J, Bennett J (1995) Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry 152:1210-1212
18. Volavka J, Cooper TB, Czobor P, Meisner M (1995) Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 52:837-845
19. Volkow ND, Fowler JS, Wang J-J, Dewey L, Schlyer D, MacGregor R, Logan J, Alexoff D, Shea C, Hitzemann R, Angrist B, Wolf AP (1993) Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 23:609-613
20. Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R, Lieberman J, Angrist B, Pappas N, Macgregor R, Burr G, Cooper T, Wolf AP (1994) Imaging endogenous dopamine competition with [C-11] raclopride in the human brain. Synapse 16: 255-262
21. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, Fowler J (1989) Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 46:482-483
22. Wong J, Zipursky R, Beiser M, Bean G (1996) Optimal haloperidol dosage for first episode schizophrenia. Biol Psychiatry 39: 513